OTCQX:MRVFF - Post by User
Comment by
need2stockupon Mar 12, 2013 7:31pm
200 Views
Post# 21119235
RE: RE: Voltaren takes commanding lead
RE: RE: Voltaren takes commanding lead Marianne you are most likey correct, but the bottom line is Pennsaid has not lived up to expectations. Need2.
World wide sales of Voltaren $ 759 million USD excluding OTC.
TOP 20 PHARMACEUTICALS DIVISION PRODUCT NET SALES – 2012
Net sales United States Brands Business franchise Indication USD millions % change in constant currencies Net sales Rest of world USD millions % change in constant currencies Total net sales USD millions % change in constant currencies |
Chronic myeloid
Gleevec/Glivec Oncology leukemia 1 698 16 2 977 – 2 4 675 0 4 |
Diovan/Co–Diovan Primary care Hypertension 2 087 – 11 2 330 – 28 4 417 – 22 – 21 |
Age-related
Lucentis Ophthalmics macular degeneration 2 398 22 2 398 17 22 |
Sandostatin Oncology Acromegaly 649 13 863 5 1512 5 8 |
Exforge Primary care Hypertension 358 10 994 18 1 352 12 16 |
Zometa Oncology Cancer complications 561 – 13 727 – 10 1 288 – 13 – 11 |
Relapsing multiple
Gilenya Neuroscience sclerosis 727 90 468 nm 1195 142 147 |
Exelon/Exelon Patch Neuroscience Alzheimer’s disease 428 14 622 – 4 1 050 – 2 2 |
Chronic myeloid
Tasigna Oncology leukemia 351 38 647 47 998 39 44 |
Galvus Primary care Diabetes 910 43 910 34 43 |
Exjade Oncology Iron chelator 251 – 3 619 11 870 2 7 |
Neoral/Sandimmun Integrated Hospital Care Transplantation 64 – 10 757 – 6 821 – 9 – 6 |
Afinitor/Votubia Oncology Breast cancer 412 142 385 49 797 80 85 |
Voltaren (excl. OTC) Additional products Inflammation/pain 1 – 75 758 1 759 – 4 0 |
Reclast/Aclasta Established medicines Osteoporosis 354 – 8 236 9 590 – 4 – 2 |
Myfortic Integrated Hospital Care Transplantation 239 20 340 14 579 12 16 |
Attention deficit/
Ritalin/Focalin Additional products hyperactivity disorder 402 1 152 8 554 1 3 |
Comtan/Stalevo Neuroscience Parkinson’s disease 147 – 31 383 0 530 – 14 – 11 |
Xolair Critical Care Asthma 504 15 504 5 12 |
Femara Oncology Breast cancer 22 – 90 416 – 37 438 – 52 – 50 |
Top 20 products total 8 751 6 17 486 3 26 237 0 4 |
Rest of portfolio 1641 –3 4275 –5 5916 –7 –4 |
Total Division sales 10 392 4 21 761 1 32 153 – 1 2 |
| |